Drugs / RC118-ADC
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05205850 | Mar 2022 → Sep 2025 overdue | neoplasm | RemeGen Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RC118-ADC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05205850 ↗ |
| Action | Inhibit | “a Claudin 18.2-targeting antibody and a microtube inhibitor” NCT05205850 ↗ |